Anesthesiology: First of two parts

New England Journal of Medicine

Volumn 337, Issue 16, 1997, Pages 1132-1141

  Wiklund, Richard A ^a   Rosenbaum, Stanley H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ATRACURIUM; ATRACURIUM BESILATE; DOXACURIUM; FENTANYL; MIVACURIUM; MORPHINE; PANCURONIUM; PIPECURONIUM; REMIFENTANIL; ROCURONIUM; SUFENTANIL; VECURONIUM;

ANALGESIA; ANESTHESIOLOGY; BLOOD TRANSFUSION; DIAGNOSTIC TEST; DRUG HALF LIFE; DRUG POTENCY; HEART SURGERY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW;

ANESTHESIOLOGY; ANESTHETICS; BLOOD TRANSFUSION; HEART DISEASES; HUMANS; NARCOTICS; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PATIENT CARE PLANNING; PREOPERATIVE CARE;

EID: 0030810819     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199710163371606     Document Type: Review

References (100)

1. Ngai SH, Mark LC, Papper EM. Pharmacologic and physiologic aspects of anesthesiology. N Engl J Med 1970;282:479-91, 541-56.
2. Stone FL. The new image. Bull N Y State Acad Anesth 1968;20:42-7.
3. Mangano DT. Preoperative risk assessment: many studies, few solutions: is a cardiac risk assessment paradigm possible? Anesthesiology 1995;83: 897-901.
4. Fischer SP. Development and effectiveness of an anesthesia preoperative evaluation clinic in a teaching hospital. Anesthesiology 1996;85:196-206.
5. Archer C, Levy AR, McGregor M. Value of routine preoperative chest x-rays: a meta-analysis. Can J Anaesth 1993;40:1022-7.
6. Narr BJ, Hansen TR, Warner MA. Preoperative laboratory screening in healthy Mayo patients: cost-effective elimination of tests and unchanged outcomes. Mayo Clin Proc 1991;66:155-9.
7. ACC/AHA guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Circulation 1996;93:1280-317.
8. Younis L, Stratmann H, Takase B, Byers S, Chaitman BR, Miller DD. Preoperative clinical assessment and dipyridamole thallium-201 scintigraphy for prediction and prevention of cardiac events in patients having major noncardiovascular surgery and known or suspected coronary artery disease. Am J Cardiol 1994;74:311-7.
9. Fiser WP, Thompson BW, Thompson AR, Eason C, Read RC. Nuclear cardiac ejection fraction and cardiac index in abdominal aortic surgery. Surgery 1983;94:736-9.
10. Prys-Roberts C, Meloche R, Foex P. Studies of anaesthesia in relation to hypertension. I. Cardiovascular responses of treated and untreated patients. Br J Anaesth 1971;43:122-37.
11. Stone JG, Foex P, Sear JW, Johnson LL, Khambatta HJ, Triner L. Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent. Anesthesiology 1988;68: 495-500.
12. Charlson ME, MacKenzie CR, Ales K, Gold JP, Fairclough G Jr, Shires GT. Surveillance for postoperative myocardial infarction after noncardiac operations. Surg Gynecol Obstet 1988;167:407-14.
13. Fleisher LA, Rosenbaum SH, Nelson AH, Jain D, Wackers FJT, Zaret BL. Preoperative dipyridamole thallium imaging and ambulatory electrocardiographic monitoring as a predictor of perioperative cardiac events and long-term outcome. Anesthesiology 1995;83:906-17.
14. Adams JE III, Sicard GA, Allen BT, et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994;330:670-4.
15. Tarhan S, Moffitt EA, Taylor WF, Giuliani ER. Myocardial infarction after general anesthesia. JAMA 1972;220:1451-4.
16. Rao TLK, Jacobs KH, El-Etr AA. Reinfarction following anesthesia in patients with myocardial infarction. Anesthesiology 1983;59:499-505.
17. Landesberg G, Luria MH, Cotev S, et al. Importance of long-duration postoperative ST-segment depression in cardiac morbidity after vascular surgery. Lancet 1993;341:715-9.
18. Hirsch IB, McGill JB, Cryer PE, White PF. Perioperative management of surgical patients with diabetes mellitus. Anesthesiology 1991;74:346-59.
19. Donahue JG, Muñoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
20. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995;332:719-24.
21. Pisciotto PT, Ciavarella D, Kurtz SR, Lane TA, Snyder EL. Blood transfusion therapy: a physician's handbook. 4th ed. Bethesda, Md.: American Association of Blood Banks, 1993.
22. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-47.
23. Nelson AH, Fleisher LA, Rosenbaum SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 1993;21:860-6.
24. Perioperative red cell transfusion. National Institutes of Health consensus development conference statement. Vol. 7. No. 4. Bethesda, Md.: NIH Office of Medical Applications of Research, 1988:1-6.
25. Fleisher LA, Rosenbaum SH, Nelson AH, Barash PG. The predictive value of preoperative silent ischemia for postoperative ischemic cardiac events in vascular and nonvascular surgery patients. Am Heart J 1991;122: 980-6.
26. Belani KG, Estrin JA. Biochemical, metabolic and hematologic effects of intraoperative processing of CPDA-1 and AS-1 packed red cells. Anesthesiology 1987;67:Suppl:A156. abstract.
27. Wiklund RA, Fabian JA, Keenan RL. Anaesthesia for major organ transplantation. In: Aitkenhead AR, Jones RM, eds. Clinical anaesthesia. London: Churchill Livingstone, 1996:485-512.
28. Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs, or miracle solutions? Anesth Analg 1996;82:390-405.
29. Hess JR. Blood substitutes. Semin Hematol 1996;33:369-78.
30. Spiess BD, Cochran RP. Perfluorocarbon emulsions and cardiopulmonary bypass: a technique for the future. J Cardiothorac Vasc Anesth 1996; 10:83-9.
31. Foldes FF, McNall PG, Borrego-Hinojosa JM. Succinylcholine: a new approach to muscular relaxation in anesthesiology. N Engl J Med 1952; 247:596-600.
32. Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 1975;47:62-5.
33. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80: 771-9.
34. MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992; 256:789-94.
35. Rosenberg H, Gronert GA. Intractable cardiac arrest in children given succinylcholine. Anesthesiology 1992;77:1054.
36. Goudsouzian NG. Recent changes in the package insert for succinylcholine chloride: should this drug be contraindicated for routine use in children and adolescents? (Summary of the discussions of the Anesthetic and Life Support Drug Advisory Meeting of the Food and Drug Administration, FDA building, Rockville, Md., June 9, 1994.) Anesth Analg 1995;80:207-8.
37. Stelzner J, Kretz FJ, Rieger A, Reinhart K. Anästhetikainduzierter Herzstillstand: Kasuistik zweier Säuglinge mit zuvor nicht bekannter Muskeldystrophie. Anaesthetist 1993;42:44-6.
38. Delphin E, Jackson D, Rothstein P. Use of succinylcholine during elective pediatric anesthesia should be reevaluated. Anesth Analg 1987;66: 1190-2.
39. Jaffe RS, Gronert GA. Neuromuscular disorders and muscle relaxants. In: Cucchiara RF, Michenfelder JD, eds. Clinical neuroanesthesia. New York: Churchill Livingstone, 1991:351-77.
40. Miller ED Jr, Sanders DB, Rowlingson JC, Berry FA Jr, Sussman MD, Epstein RM. Anesthesia-induced rhabdomyolysis in a patient with Duchenne's muscular dystrophy. Anesthesiology 1978;48:146-8.
41. Miller RD, Rupp SM, Fisher DM, Cronnelly R, Fahey MR, Sohn YJ. Clinical pharmacology of vecuronium and atracurium. Anesthesiology 1984;61:444-53.
42. Brull SJ, Silverman DG. Intraoperative use of muscle relaxants. Anesth Clin North Am 1993;11:325-44.
43. Hughes R, Chapple DJ. The pharmacology of atracurium: a new competitive neuromuscular blocking agent. Br J Anaesth 1981;53:31-44.
44. Stiller RL, Cook DR, Chakravorti S. In vitro degradation of atracurium in human plasma. Br J Anaesth 1985;57:1085-8.
45. Basta SJ, Savarese JJ, Ali HH, Moss J, Gionfriddo M. Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine. Br J Anaesth 1983;55:Suppl 1:105S-106S.
46. Eastwood NB, Boyd AH, Parker CJ, Hunter JM. Pharmacokinetics of 1R-cis 1′R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth 1995;75:431-5.
47. Littlejohn IH, Abhay K, el Sayed A, Broomhead CJ, Duvaldestin P, Flynn PJ. Intubating conditions following 1R CIS, 1′R CIS atracurium (51W89): a comparison with atracurium. Anaesthesia 1995;50:499-502.
48. Boyd AH, Eastwood NB, Parker CJ, Hunter JM. Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. Br J Anaesth 1996;76:382-8.
49. Savarese JJ, Ali HH, Basta SJ, et al. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U): a short-acting nondepolarizing ester neuromuscular blocking drug. Anesthesiology 1988;68:723-32.
50. Brull SJ, Silverman DG. Pulse width, stimulus intensity, electrode placement, and polarity during assessment of neuromuscular block. Anesthesiology 1995;83:702-9. [Erratum, Anesthesiology 1996;84:1014.]
51. Savage DS, Sleigh T, Carlyle I. The emergence of ORG NC 45, 1-[(2β,3α,5α,16β,17β)-3,17-bis(acetlyoxy)-2-(1- piperidinyl)-androstan-16-y1]-1-methylpiperidinium bromide, from the pancuronium series. Br J Anaesth 1980;52:Suppl 1:3S-9S.
52. van den Brock L, Wierda JM, Smeulers NJ, van Santen GJ, Leclercq MG, Hennis PJ. Clinical pharmacology of rocuronium (Org 9426): study of the time course of action, dose requirement, reversibility, and pharmacokinetics. J Clin Anesth 1994;6:288-96.
53. Larijani GE, Bartkowski RR, Azad SS, et al. Clinical pharmacology of pipecuronium bromide. Anesth Analg 1989;68:734-9.
54. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992;327:524-8.
55. Muir AW, Houston J, Green KL, Marshall RJ, Bowman WC, Marshall IG. Effects of a new neuromuscular blocking agent (ORG 9426) in anaesthetized cats and pigs and in isolated nerve-muscle preparations. Br J Anaesth 1989;63:400-10.
56. Meyer KC, Prielipp RC, Grossman JE, Coursin DB. Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesth Analg 1994;78:772-4.
57. Prielipp RC, Coursin DB, Scuderi PE, et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 1995;81:3-12.
58. Coda BA. Opioids. In: Barash PG, Cullen BF, Stoelting RK, eds. Clinical anesthesia. 3rd ed. Philadelphia: Raven Lippincott, 1996:329-58.
59. Lowenstein E, Hallowell P, Levine FH, Daggett WM, Austen WG, Laver MB. Cardiovascular response to large doses of intravenous morphine in man. N Engl J Med 1969;281:1389-93.
60. Bürkle H, Dunbar S, Van Aken H. Remifentanil: a novel, short-acting, μ-opioid. Anesth Analg 1996;83:646-51.
61. Freund FG, Martin WE, Wong KC, Hornbein TF. Abdominal-muscle rigidity induced by morphine and nitrous oxide. Anesthesiology 1973;38: 358-62.
62. Bowdle TA. Myoclonus following sufentanil without EEG seizure activity. Anesthesiology 1987;67:593-5.
63. Bowdle TA, Rooke GA. Postoperative myoclonus and rigidity after anesthesia with opioids. Anesth Analg 1994;78:783-6.
64. Kofke WA, Garman RH, Janosky J, Rose ME. Opioid neurotoxicity: neuropathologic effects in rats of different fentanyl congeners and the effects of hexamethonium-induced normotension. Anesth Analg 1996;83: 141-6.
65. Eger EI II, Lundgren C, Miller SL, Stevens WC. Anesthetic potencies of sulfur hexafluoride, carbon tetrafluoride, chloroform, and Ethrane in dogs: correlation with the hydrate and lipid theories of anesthetic action. Anesthesiology 1969;30:129-35.
66. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature 1994;367:607-14.
67. Koblin DD, Chortkoff BS, Laster MJ, Eger EI II, Halsey MJ, Ionescu P. Polyhalogenated and perfluorinated compounds that disobey the Meyer-Overton hypothesis. Anesth Analg 1994;79:1043-8.
68. Hartung J. Twenty-four of twenty-seven studies show a greater incidence of emesis associated with nitrous oxide than with alternative anesthetics. Anesth Analg 1996;83:114-6.
69. Divatia JV, Vaidya JS, Badwe RA, Hawaldar RW. Omission of nitrous oxide during anesthesia reduces the incidence of postoperative nausea and vomiting: a meta-analysis. Anesthesiology 1996;85:1055-62.
70. Hadzic A, Glab K, Sanborn KV, Thys DM. Severe neurologic deficit after nitrous oxide anesthesia. Anesthesiology 1995;83:863-6.
71. Kenna JG, Jones RM. The organ toxicity of inhaled anesthetics. Anesth Analg 1995;81:Suppl:S51-S66.
72. Summary of the National Halothane Study: possible association between halothane anesthesia and postoperative hepatic necrosis. JAMA 1966;197:775-88.
73. Brown BR Jr, Gandolfi AJ. Adverse effects of volatile anaesthetics. Br J Anaesth 1987;59:14-23.
74. Gencarelli PJ, Miller RD, Eger EI II, Newfield P. Decreasing enflurane concentrations and d-tubocurarine neuromuscular blockade. Anesthesiology 1982;56:192-4.
75. Stevens WC, Cromwell TH, Halsey MJ, Eger EI II, Shakespeare TF, Bahlman SH. The cardiovascular effects of a new inhalation anesthetic, Forane, in human volunteers at constant arterial carbon dioxide tension. Anesthesiology 1971;35:8-16.
76. Reiz S, Balfors E, Sorensen MB, Ariola S Jr, Friedman A, Truedsson H. Isoflurane - a powerful coronary vasodilator in patients with coronary artery disease. Anesthesiology 1983;59:91-7.
77. Buffington CW, Davis KB, Gillispie S, Pettinger M. The prevalence of steal-prone coronary anatomy in patients with coronary artery disease: an analysis of the Coronary Artery Surgery Study Registry. Anesthesiology 1988;69:721-7.
78. Slogoff S, Keats AS, Dear WE, et al. Steal-prone coronary anatomy and myocardial ischemia associated with four primary anesthetic agents in humans. Anesth Analg 1991;72:22-7.
79. Eger EI II. New inhaled anesthetics. Anesthesiology 1994;80:906-22.
80. Idem. Desflurane animal and human pharmacology: aspects of kinetics, safety, and MAC. Anesth Analg 1992;75:Suppl:S3-S7.
81. Muzi M, Lopatka CW, Ebert TJ. Desflurane-mediated neurocirculatory activation in humans: effects of concentration and rate of change on responses. Anesthesiology 1996;84:1035-42.
82. Helman JD, Leung JM, Bellows WH, et al. The risk of myocardial ischemia in patients receiving desflurane versus sufentanil anesthesia for coronary artery bypass graft surgery: the S.P.I. Research Group. Anesthesiology 1992;77:47-62.
83. Todd MM, Warner DS, Sokoll MD, et al. A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy: propofol/ fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide. Anesthesiology 1993;78:1005-20.
84. Gonsowski CT, Laster MJ, Eger EI II, Ferrell LD, Kerschmann RL. Toxicity of compound A in rats: effect of a 3-hour administration. Anesthesiology 1994;80:556-65.
85. Idem. Toxicity of compound A in rats: effect of increasing duration of administration. Anesthesiology 1994;80:566-73.
86. Morio M, Fujii K, Satoh N, et al. Reaction of sevoflurane and its degradation products with soda lime: toxicity of the byproducts. Anesthesiology 1992;77:1155-64.
87. Frink EJ Jr, Ghantous H, Malan TP, et al. Plasma inorganic fluoride with sevoflurane anesthesia: correlation with indices of hepatic and renal function. Anesth Analg 1992;74:231-5.
88. Sebel PS, Lowdon JD. Propofol: a new intravenous anesthetic. Anesthesiology 1989;71:260-77.
89. Smith I, White PF, Nathanson M, Gouldson R. Propofol: an update on its clinical use. Anesthesiology 1994;81:1005-43.
90. Bloomfield EL, Masaryk TJ, Caplin A, et al. Intravenous sedation for MR imaging of the brain and spine in children: pentobarbital versus propofol. Radiology 1993;186:93-7.
91. Scheiber G, Ribeiro FC, Karpienski H, Strehl K. Deep sedation with propofol in preschool children undergoing radiation therapy. Paediatr Anaesth 1996;6:209-13.
92. Crawford M, Pollock J, Anderson K, Glavin RJ, MacIntyre D, Vernon D. Comparison of midazolam with propofol for sedation in outpatient bronchoscopy. Br J Anaesth 1993;70:419-22.
93. Chamorro C, de Latorre FJ, Montero A, et al. Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial. Crit Care Med 1996;24: 932-9.
94. Higgins TL, Yared JP, Estafanous FG, Coyle JP, Ko HK, Goodale DB. Propofol versus midazolam for intensive care unit sedation after coronary artery bypass grafting. Crit Care Med 1994;22:1415-23.
95. Borgeat A, Wilder-Smith O, Forni M, Suter PM. Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. Can J Anaesth 1994;41:1117-9.
96. Veber B, Gachot B, Bedos JP, Wolff M. Severe sepsis after intravenous injection of contaminated propofol. Anesthesiology 1994;80:712-3.
97. Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995;333:147-54.
98. Blouin RT, Seifert HA, Babenco HD, Conard PF, Gross JB. Propofol depresses the hypoxic ventilatory response during conscious sedation and isohypercapnia. Anesthesiology 1993;79:1177-82.
99. Committee on Drugs, Section on Anesthesiology. Guidelines for the elective use of conscious sedation, deep sedation, and general anesthesia in pediatric patients. Pediatrics 1985;76:317-21.
100. Guidelines on sedation and analgesia by nonanesthesiologists. Park Ridge, Ill.: American Society of Anesthesiologists, 1995.